Start Date
July 9, 2025
Primary Completion Date
July 17, 2025
Study Completion Date
July 17, 2025
TQA3605 tablets Placebo
Placebo contains no active substance.
TQA3605 Tablets
TQA3605 tablets is core protein allosteric modulators
Entecavir dispersible tablets
Entecavir dispersible tablets is an inhibitor of hepatitis B virus replication.
Beijing Ditan Hospital Capital Medical University, Beijing
Beijing Youan Hospital,Capital Medical University, Beijing
The First Hospital of Jilin University, Changchun
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai
Shanghai Tongren Hospital, Shanghai
Jiangsu Provincial People's Hospital, Nanjing
The Second Hospital of Nanjing, Nanjing
Naniing Drum Tower Hospital, Nanjing
Zhenjiang Third People's Hospital, Zhenjiang
The Fifth People's Hospital of Wuxi, Wuxi
The Fifth People's Hospital of Suzhou, Suzhou
The Second Hospital of Shandong University, Jinan
Shandong Provincial Clinical Center for Public Health, Jinan
Yiwu Central Hospital, Yiwu
The First Affiliated Hospital of Nanchang University, Nanchang
Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou
The Second Affiliated Hospital of Chongqing Medical University, Chongqing
The Southwest Hospital of AMU, Chongqing
The First Hospital of Changsha, Changsha
Zhengzhou No.6 peoples Hospital, Zhengzhou
Henan Provincial People's Hospital, Zhengzhou
NanFang Hospital, Guangzhou
Peking University Shenzhen Hospital, Shenzhen
The First Affiliated Hospital of GUANGXI Medical University, Nanning
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an
Xi'an Jiaotong University Second Affiliated Hospital, Xi'an
The First Affiliated Hospital of Xinjiang Medical University, Ürümqi
Hebei Medical University Third Hospital, Shijiazhuang
Shengjing Hospital Affiliated to China Medical University, Shenyang
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY